Werewolf Therapeutics Inc logo

HOWL

Werewolf Therapeutics Inc

$6.27

Earnings Summary

Revenue
$0Mn
Net Profits
$-15.34Mn
Net Profit Margins
-Inf%
PE Ratio
0.98

Highlights

Revenue:

Werewolf Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2022. On a quarterly growth basis, Werewolf Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Net Profits:

Werewolf Therapeutics Inc’s net profit fell -106.36% since last year same period to $-15.34Mn in the Q1 2022. On a quarterly growth basis, Werewolf Therapeutics Inc has generated 14.14% jump in its net profits since last 3-months.

Net Profit Margins:

Werewolf Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2022. On a quarterly growth basis, Werewolf Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

PE Ratio:

Werewolf Therapeutics Inc’s price-to-earnings ratio after this Q1 2022 earnings stands at 0.98.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Werewolf Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.61
EPS Estimate Current Year
-0.61

Highlights

EPS Estimate Current Quarter:

Werewolf Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a -15.09% fall from last quarter’s estimates.

EPS Estimate Current Year:

Werewolf Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.61.

Key Ratios

Key ratios of the Werewolf Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.56
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.4
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Werewolf Therapeutics Inc’s earning per share (EPS) jumped 99.33% since last year same period to -0.56 in the Q1 2022. This indicates that the Werewolf Therapeutics Inc has generated 99.33% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Werewolf Therapeutics Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Werewolf Therapeutics Inc’s return on equity (ROE) stands at -0.4.

Dividend Per Share (DPS):

Werewolf Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.61
-0.56
8.2%

Company Information

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors.The company is continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

Organisation
Werewolf Therapeutics Inc
Employees
28